UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23

Benzinga · 1d ago
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $19 to $23.